Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 74 Neoplasms 34 Carcinoma, Non-Small-Cell Lung 25 Colorectal Neoplasms 17 Neoplasm Metastasis 15 Glioma 11 Thyroid Neoplasms 10 Multiple Myeloma 10 Pancreatic Neoplasms 9 Thyroid Carcinoma, Anaplastic 8 Hematologic Neoplasms 8 Brain Neoplasms 8 Lung Neoplasms 6 Triple Negative Breast Neoplasms 5 Skin Neoplasms 5 Neurofibromatosis 1 5 Astrocytoma 5 Recurrence 4 Rectal Neoplasms 4 Lymphoma 4 Glioblastoma 4 Colonic Neoplasms 4 Cholangiocarcinoma 4 Breast Neoplasms 4 Uveal Melanoma 3 Oligodendroglioma 3 Neurofibroma, Plexiform 3 Leukemia, Myeloid, Acute 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3

Interventions

Nivolumab 14 Surveys and Questionnaires 7 Ipilimumab 6 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 relatlimab 3 Vorinostat 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 regorafenib 2 apatinib 2 abemaciclib 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Dasatinib 2 Cisplatin 2 Chlorogenic Acid 2 Capecitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡